It is Time to Buy Agios Pharma (NASDAQ:AGIO), Citigroup Says. Stock May Be Worth $117.0000

May 24, 2018 - By Michael Collier

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Logo

Investors sentiment increased to 1.22 in 2017 Q4. Its up 0.01, from 1.21 in 2017Q3. It is positive, as 19 investors sold Agios Pharmaceuticals, Inc. shares while 48 reduced holdings. 27 funds opened positions while 55 raised stakes. 45.70 million shares or 2.27% more from 44.69 million shares in 2017Q3 were reported.

Mutual Of America Mgmt Lc holds 0.03% or 30,567 shares in its portfolio. Schwab Charles Inv, California-based fund reported 121,975 shares. Ohio-based Fifth Third National Bank has invested 0% in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). Tiaa Cref Invest Limited Liability Corp has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 108,369 shares. Alps Advisors owns 0.02% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 53,416 shares. Principal Finance Grp, Iowa-based fund reported 13,362 shares. Guardian has 0.54% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 663,089 shares. Pub Employees Retirement Association Of Colorado holds 6,769 shares. Moreover, Pnc Finance Services Grp has 0% invested in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 99 shares. Vanguard Gru Inc holds 3.30 million shares. Citigroup Inc holds 0% or 7,393 shares. 7,462 are held by Weiss Asset Mgmt Lp. Blackrock holds 0.01% of its portfolio in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) for 2.81M shares. Columbia Wanger Asset Lc reported 760,116 shares. Nuveen Asset Ltd Liability Com, a Illinois-based fund reported 8,550 shares.

Since January 10, 2018, it had 1 insider purchase, and 23 sales for $18.55 million activity. Schenkein David P sold $3.71 million worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Tuesday, January 23. Hoerter Steven L. sold 2,050 shares worth $176,198. Bowden Christopher sold $170,190 worth of stock or 2,000 shares. Shares for $161,250 were sold by Alenson Carman. Another trade for 200 shares valued at $16,688 was bought by Scadden David. Foster-Cheek Kaye I also sold $557,396 worth of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Monday, March 19.

Why Has Citigroup Given Agios Pharma (NASDAQ:AGIO) a $117.0000 Price Target

In a research report issued to clients and investors today, Citigroup analysts began Agios Pharma (NASDAQ:AGIO) coverage with Buy rating, and a $117.0000 target.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Coverage

Among 4 analysts covering Agios Pharma (NASDAQ:AGIO), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Agios Pharma has $95 highest and $80.0 lowest target. $89.33’s average target is 0.45% above currents $88.93 stock price. Agios Pharma had 5 analyst reports since February 14, 2018 according to SRatingsIntel. JP Morgan maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) on Thursday, February 15 with “Overweight” rating. The firm has “Outperform” rating by Credit Suisse given on Wednesday, April 11. Credit Suisse maintained Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) rating on Thursday, February 15. Credit Suisse has “Buy” rating and $80.0 target. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, February 14.

The stock increased 3.48% or $2.99 during the last trading session, reaching $88.93. About 600,449 shares traded or 62.46% up from the average. Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has risen 41.40% since May 24, 2017 and is uptrending. It has outperformed by 29.85% the S&P500.

Analysts await Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) to report earnings on August, 14. They expect $-1.66 earnings per share, up 6.74 % or $0.12 from last year’s $-1.78 per share. After $-1.63 actual earnings per share reported by Agios Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 1.84 % negative EPS growth.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. The company has market cap of $5.12 billion. It is developing Enasidenib, a potent inhibitor of the mutated isocitrate dehydrogenase 2 protein that is in Phase 1/2 clinical trial for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase 3 clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination trial for patients with newly diagnosed AML. It currently has negative earnings. The firm is also developing Ivosidenib, a potent inhibitor of the mutated IDH1 protein, which is in Phase 1 clinical trial for patients with advanced hematologic malignancies with an IDH1 mutation; Phase 1 clinical trial for advanced solid tumors; Phase 3 clinical trial for patients with nonresectable or metastatic cholangiocarcinoma with an IDH1 mutation; Phase 1b frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase 1/2 frontline combination and Phase 3 clinical trials for newly diagnosed AML patients.

More notable recent Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) news were published by: Nasdaq.com which released: “Agios Announces Revised Starting Time of 8:00am ET for Investor Day and First Quarter 2018 Financial Results …” on April 27, 2018, also Nasdaq.com with their article: “Agios to Present New Clinical Data from its IDH Programs at ASCO” published on May 16, 2018, Seekingalpha.com published: “A Fresh Look At Celgene After Q1 And New Info On Ozanimod” on May 08, 2018. More interesting news about Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) were released by: Seekingalpha.com and their article: “Agios Pharmaceuticals (AGIO) Investor Presentation – Slideshow” published on May 04, 2018 as well as Nasdaq.com‘s news article titled: “Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial …” with publication date: May 17, 2018.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: